NetScientific PLC Results of General Meeting (8194H)

TIDMNSCI

RNS Number : 8194H

NetScientific PLC

12 June 2017

12 June 2017

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO.

THIS ANNOUNCEMENT IS NOT AN OFFER TO SELL OR THE SOLICITATION OF AN OFFER TO BUY ANY ORDINARY SHARES OR OTHER SECURITIES OF THE COMPANY AND NEITHER THIS ANNOUNCEMENT NOR ANYTHING HEREIN FORMS THE BASIS FOR ANY CONTRACT OR COMMITMENT WHATSOEVER. ORDINARY SHARES OR OTHER SECURITIES OF THE COMPANY MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES OF AMERICA ABSENT REGISTRATION OR AN EXEMPTION FROM REGISTRATION AND THE ORDINARY SHARES DESCRIBED HEREIN WILL BE SOLD IN ACCORDANCE WITH ALL APPLICABLE LAWS AND REGULATIONS.

NetScientific plc

("NetScientific" or the "Company")

Result of General Meeting

London, UK - 12 June 2017: On 25 May 2017, NetScientific, the transatlantic healthcare IP commercialisation Group, announced a conditional Placing, Subscription and an Additional Fundraising (the "Offer").

It was announced earlier today that the Offer conditionally raised a total of GBP8.1m before expenses.

The Company is pleased to announce that, at its General Meeting held earlier today, the resolutions as set out in the Notice of General Meeting sent to shareholders on 26 May 2017 in reference to the Offer, were duly passed. Admission of the New Ordinary Shares relating to the Offer is expected at 8.00 a.m. on 13 June 2017.

Capitalised terms in this announcement have the meanings given to them in the Circular dated 26 May 2017.

For more information, please contact:

 
 NetScientific plc 
 François R. Martelet, M.D.,                        Tel: +44 (0)20 
  CEO                                                         3514 1800 
 Ian Postlethwaite, CFO 
 
 Stifel Nicolaus Europe Limited                          Tel: +44 (0)20 
  (NOMAD, broker and bookrunner)                              7710 7600 
 Jonathan Senior / David Arch / 
  Ben Maddison 
 
 Liberum Capital Limited (placing                        Tel: +44 (0)20 
  agent)                                                      3100 2000 
 David Parsons / Christopher Britton 
 
 Consilium Strategic 
 Communications                              Tel: [phone] 
 Mary-Jane Elliott / 
 Jessica Hodgson / Chris 
 Welsh / Laura Thornton 
 [e-mail] 
 
 
 

About NetScientific

NetScientific is an IP commercialisation group focused on healthcare with an investment strategy focused on sourcing, funding and commercialising technologies that significantly improve the health and well-being of people with chronic diseases. For more information, please visit the website at www.netscientific.net

Stifel Nicolaus Europe Limited ("Stifel") is authorised and regulated by the FCA in the United Kingdom and is acting exclusively as nominated adviser and bookrunner to the Company (for the purposes of the AIM Rules for Companies) and no one else in connection with Admission, the Placing and the matters set out in this announcement. Stifel will not regard any other person as its customer or be responsible to any other person for providing the protections afforded to customers of Stifel nor for providing advice in relation to the transactions and arrangements detailed in this announcement for which the Company and the Directors are solely responsible and, without limiting the statutory rights of any recipient of this announcement, no liability is accepted by Stifel for the accuracy of any information or opinions contained in this announcement or for omissions of any material information for which it is not responsible. Stifel is not making any representation or warranty, express or implied, as to the contents of this announcement. The responsibilities of Stifel as the Company's nominated adviser and bookrunner solely for the purposes of the AIM Rules for Nominated Advisers are owed solely to the London Stock Exchange and are not owed to the Company or any Director or to any other person in respect of his decision to invest in the Company in reliance on any parts of this announcement.

Liberum Capital Limited ("Liberum"), which is authorised and regulated in the United Kingdom by the FCA, is acting exclusively for the Company and no other person in connection with the Placing. Liberum will not regard any other person as its customer or be responsible to any other person for providing the protections afforded to customers of Liberum nor for providing advice in relation to the transactions and arrangements detailed in this announcement for which the Company and the Directors are solely responsible and, without limiting the statutory rights of any person to whom this announcement is issued, no liability is accepted by Liberum for the accuracy of any information or opinions contained in this announcement or for the omission of any material information for which it is not responsible. Liberum is not making any representation or warranty, express or implied, as to the contents of this announcement.

This information is provided by RNS

The company news service from the London Stock Exchange

END

ROMSFUFSEFWSEIM

(END) Dow Jones Newswires

June 12, 2017 07:02 ET (11:02 GMT)